Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHDGlobeNewsWire • 12/22/20
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPNGlobeNewsWire • 11/26/20
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/04/20
Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/03/20
Supernus Submits NDA for SPN-830 for Continuous Treatment of ON-OFF Episodes in Adults with Parkinson’s Disease Who Have Failed Two TreatmentsGlobeNewsWire • 09/14/20
Supernus to Present at the Morgan Stanley 18th Annual Global Healthcare ConferenceGlobeNewsWire • 09/09/20
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/19/20
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q2 Earnings Expected to DeclineZacks Investment Research • 07/28/20